# A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07365241/  
OnCo record `nct07365241` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing ABBV-706 in non-small-cell lung cancer, now recruiting.

## Summary

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07365241, led by AbbVie, and recruiting on the registry. Official title: A Phase 3 Randomised, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC). Planned enrolment is 531 participants (estimated). The study started in 2026-07-02 and primary completion is expected in 2030-09. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07365241
- Phase: 3
- Setting: A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)
- Sponsor: AbbVie
- Enrolled: 531

## Sources

- ClinicalTrials.gov NCT07365241: https://clinicaltrials.gov/study/NCT07365241

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [ABBV-706](https://onco.cc/drugs/abbv-706/), [Amrubicin](https://onco.cc/drugs/amrubicin/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct07365241.json